X0508 4 2026-02-10 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817160 Hansen Gwenn C/O NURIX THERAPEUTICS, INC. 1600 SIERRA POINT PKWY BRISBANE CA 94005 0 1 0 0 Chief Scientific Officer 0 Employee Stock Option (right to buy) 16.45 2026-02-10 4 A 0 93750 0 A 2036-02-09 Common Stock 93750 93750 D Restricted Stock Units 0 2026-02-10 4 A 0 42875 0 A Common Stock 42875 42875 D The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen 2026-02-10